Physician profile
Eric L Caplan
NPI 1023125655
$290,224.31
in general payments reported to CMS, 2019-2025
33 companies · $44K in 2025
The $44K reported for 2025 was more than what 95% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,956 · 2020: $26K · 2021: $58K · 2022: $44K · 2023: $54K · 2024: $55K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $128K · Food and Beverage: $9,478 · Consulting Fee: $8,500 · Travel and Lodging: $6,302 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $127,725.00 |
| Food and Beverage | $9,478.01 |
| Consulting Fee | $8,500.00 |
| Travel and Lodging | $6,301.77 |
| Education | $156.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $277,718.33 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $3,509.97 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $1,754.38 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Genentech USA, INC. | $1,556.89 | 2022-2025 | Xolair |
| Genzyme Corporation | $1,331.46 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $620.02 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $560.53 | 2021-2025 | |
| Grifols USA, LLC | $541.71 | 2021-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Octapharma USA, INC. | $263.61 | 2019-2021 | |
| Pfizer INC. | $251.34 | 2019-2024 | Gelfoam, Thrombin-Jmi |
| Inspire Medical Systems, INC. | $246.06 | 2023-2025 | Inspire |
| Amgen INC. | $222.73 | 2021-2025 | Tezspire |
| Csl Behring | $201.65 | 2022-2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $156.85 | 2019-2022 | |
| Abbvie INC. | $149.56 | 2022-2025 | Rinvoq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $137.94 | 2021-2025 | Joenja, Ruconest |
| Optinose US, INC. | $131.89 | 2019-2020 | |
| Kaleo, INC. | $126.50 | 2020-2024 | Auvi-Q |
| Alk-Abello, INC | $123.20 | 2023 | Standardized Mite D. Farinae, Timothy, Standardized, Alternaria Tenuis |
| Sanofi-Aventis U.S. LLC | $122.85 | 2022-2024 | |
| Shire North American Group INC | $96.73 | 2019 | |
| Aerin Medical INC. | $93.93 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $60.24 | 2022-2024 | Orladeyo |
| Sunovion Pharmaceuticals INC. | $42.61 | 2019 | |
| Blueprint Medicines Corporation | $39.99 | 2024 | Ayvakit |
| Aimmune Therapeutics, INC. | $39.48 | 2021-2022 | |
| Organon LLC | $25.48 | 2025 | Vtama |
| Genentech, INC. | $22.39 | 2019 | |
| Agiliti Surgical, INC. | $20.24 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.30 | 2025 | Alvesco |
| Leo Pharma INC. | $15.01 | 2023 | Adbry |
| Bio Products Laboratory USA, INC. | $13.69 | 2019 | |
| Sanofi Pasteur INC. | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Caplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.